JPMorgan Chase & Co. Grows Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

JPMorgan Chase & Co. raised its position in Structure Therapeutics Inc. (NASDAQ:GPCR) by 302.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,936 shares of the company’s stock after purchasing an additional 25,500 shares during the quarter. JPMorgan Chase & Co. owned 0.06% of Structure Therapeutics worth $1,489,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Assetmark Inc. grew its stake in shares of Structure Therapeutics by 120.0% in the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after buying an additional 719 shares in the last quarter. Quarry LP acquired a new stake in shares of Structure Therapeutics in the second quarter valued at about $79,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Structure Therapeutics by 60.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock valued at $158,000 after buying an additional 1,420 shares in the last quarter. Dearborn Partners LLC acquired a new stake in shares of Structure Therapeutics in the third quarter valued at about $202,000. Finally, Bank Pictet & Cie Europe AG acquired a new stake in shares of Structure Therapeutics in the third quarter valued at about $206,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GPCR has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a research note on Thursday, December 19th. Stifel Nicolaus initiated coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective for the company. Finally, JMP Securities restated a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $81.29.

Structure Therapeutics Stock Up 0.1 %

Shares of NASDAQ GPCR opened at $27.96 on Friday. The firm has a market cap of $1.60 billion, a PE ratio of -37.78 and a beta of -2.78. The business has a 50 day moving average price of $30.21 and a two-hundred day moving average price of $35.83. Structure Therapeutics Inc. has a fifty-two week low of $23.50 and a fifty-two week high of $62.74.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.